By Fineline Cube Akeso Biopharma (HKG: 9926) announced that the National Medical Products Administration (NMPA) of China has approved the supplemental New Drug Application (sNDA) for ivonescimab — its first-in-class Immuno-Oncology 2.0 cornerstone drug — in combination with chemotherapy for the first-line treatment of advanced squamous non-small cell lung cancer (sq-NSCLC).
Regulatory Milestone
| Item | Detail |
|---|---|
| Company | Akeso Biopharma (HKG: 9926) |
| Agency | NMPA (China) |
| Approval Type | Supplemental New Drug Application (sNDA) |
| Drug | Ivonescimab (first-in-class IO 2.0 bispecific) |
| Indication | First-line advanced squamous NSCLC, in combination with chemotherapy |
| Approval Date | 12 Aug 2026 |
| Significance | 3rd approved lung cancer indication for ivonescimab |
Clinical Evidence – Redefining the Standard of Care
- Trial Design: Randomized, double-blind, controlled Phase III clinical trial
- Comparator: PD-1 antibody plus chemotherapy — the incumbent first-line standard
- Dual Endpoints Met: The regimen demonstrated statistically significant and clinically meaningful improvements in both progression-free survival (PFS) and overall survival (OS)
- World First: The first regimen globally to achieve dual PFS and OS superiority against a PD-1-based standard in a controlled Phase III setting, thereby redefining the standard of care for first-line sq-NSCLC
Market Impact & Outlook
- IO 2.0 Leadership: The approval reinforces ivonescimab’s position as the anchor of Akeso’s Immuno-Oncology 2.0 franchise, extending its commercial footprint to a third lung cancer indication.
- Large Addressable Market: Squamous NSCLCL represents a substantial share of China’s lung cancer burden, making first-line combination approval a material revenue driver.
- Competitive Edge: Demonstrating PFS + OS benefit over the entrenched PD-1 plus chemotherapy backbone provides a differentiated evidence base that single-agent checkpoint inhibitors have struggled to match in head-to-head settings.
- Next Steps: Commercial terms and international regulatory timelines were not disclosed.
Forward‑Looking Statements
This brief contains forward-looking statements regarding the commercialization and clinical potential of ivonescimab. Actual results may differ due to risks including market adoption, pricing and reimbursement dynamics, and competitive developments in immuno-oncology.-Fineline Info & Tech